FDA approved Crizotinib (Xalkori®, Pfizer) for treatment of refractory or relapsed anaplastic lymphoma kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL) in children and young adults.

Crizotinib (Xalkori®, Pfizer) has been approved by the Food and Drug Administration (FDA) n the USA on 14 January 2021 for the treatment of refractory or relapsed anaplastic lymphoma kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL) in children and young adults.

During the first ACCELERATE Paediatric Strategy Forum on ALK inhibition in paediatric malignancies organised in January 2017, ALK was identified as an important target for certain paediatric tumours. One of these paediatric tumours was ALCL. There was an unmet medical need for this type of cancer and it was identified that ALK inhibitors could play an important role. During an update meeting on 13 & 14 January 2021, the critical role of ALK inhibitors in ALCL was once again highlighted.

ALK-positive ALCL is a form of cancer which usually affects children and young adults. ALCL is a form of non-Hodgkin lymphoma. The approval of crizotinib, as non-chemotherapy, targeted drug, widens the therapeutic weapons for treating this disease. We are pleased with the role that ACCELERATE and our Paediatric Strategy Forums continue to play in ALCL and other childhood malignancies.

Paediatric Strategy Forums are multi-stakeholder meetings aiming to evaluate the current state of the science, facilitate dialogue and provide an opportunity for constructive discussions between relevant stakeholders.  These are scientific meetings aimed at facilitating prioritisation in order to better meet the needs of patients and to increase feasibility of paediatric developments.

More information about the first ACCELERATE Paediatric Strategy Forum on ALK inhibitors: https://www.accelerate-platform.org/6th-paediatric-strategy-forum/past-events/1st-paediatric-strategy-forum/